NewsMarkets

Health

Eli Lilly's Foundayo pill eases sleep apnea in late-stage trial

The company plans to file for US approval of the GLP-1 drug by year-end, though it appears less effective than its injectable Zepbound.

5 publishers · 5 articles · first seen 9 Nov 2026 · updated 5d ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

This story has stopped developing; this page is its permanent record. More from that day

The story so far

5 publishers have covered this in 5 articles since 9 Nov 2026. STAT published first, on 9 November at 14:30 UTC; CNBC followed 0 min later. The most recent article, from MedPageToday.com - medical news for physicians, appeared on 10 November at 21:49 UTC.

Outlets reporting it: CNBC (major outlet), STAT, Quartz, Scientific American, MedPageToday.com - medical news for physicians.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval CNBC ·
  2. GLP-1 Pill Shows Benefit in Sleep Apnea MedPageToday.com - medical news for physicians
  3. Eli Lilly shows GLP-1 weight-loss pill Foundayo can dramatically improve sleep apnea Scientific American
  4. Eli Lilly's obesity pill showed it can ease sleep apnea in a late-stage trial Quartz
  5. STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies STAT

In this story

  • Eli Lilly
  • Foundayo
  • FDA
  • Zepbound
Embed this story

Paste this into any web page to show the live odds, with a link back here.